The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis
Date:
06/04/2025
Topics:
Citation:
Soni H, Tyagi S, Mane K, Shelke AM, Kumar P, Kaya F, Alland D, Zimmerman M, Freundlich JS, Nuermberger EL. The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0013025. doi: 10.1128/aac.00130-25. Epub 2025 Apr 23. PMID: 40265947; PMCID: PMC12135538.
Abstract
JSF-3285 is a promising preclinical candidate for tuberculosis that potently targets the Mycobacterium tuberculosis β-ketoacyl-ACP synthase KasA. In mouse models of acute, sub-acute, chronic, and relapse infection, JSF-3285 offers substantial activity in combination with bedaquiline and pretomanid, which could be applicable for both drug-sensitive and drug-resistant infections.